At a glance

ClinicalIndex Comparison Record

Phase 3Completed

Drug / intervention

risperidone +2 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00065273

NCT00065273Phase 3Completed

Compare CT.gov

Severe Aberrant Behavior Among Persons With Mental Retardation. Project III: Behavioral Selectivity of Atypical Neuroleptic Drugs: Effects on Cognitive and Social Behaviors

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·interventional·Posted Jul 22, 2003·Updated Jun 24, 2005

In Brief

A Phase 3 clinical trial evaluating risperidone, clozapine, and 1 other intervention for Mental Retardation and Developmental Delay Disorder. Completed, across 1 site.

Detailed Summary

Psychiatric drugs are often used to treat behavioral symptoms of mental retardation/developmental delay (MR/DD). These drugs can cause serious side effects. Newer drugs may have decreased side effects. This study will compare new and old drugs used to treat behavioral symptoms in people with MR/DD.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsMental Retardation, Developmental Delay Disorder

CountriesUnited States

Collaborators--

Timeline

Phase 3CompletedFinished

199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartJul 1998

Study CompletionJun 2001

First PostedJul 2003

TodayJul 2026

First PostedJul 22, 2003

Enrollment StartJul 1, 1998

Study CompletionJun 1, 2001

TodayJul 2, 2026

Posted 22.9 years ago

Interventions

risperidonedrug

clozapinedrug

olanzapinedrug